Vildagliptin: all 152 studies that test it

Page 2 of 2. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.

• Pharmacokinetic Study of LAF237 and Its Metabolites in Mild Renal Impaired PatientsCompletedNCT00572650Phase 1
• Pharmacokinetic Study of Vildagliptin in Patients With Renal ImpairmentCompletedNCT00567047Phase 1
• Vildagliptin 100 mg Once Daily vs. Placebo as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With MetforminCompletedNCT00494884Phase 3
• A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus MetforminCompletedNCT00468039Phase 3
• Safety, Tolerability, Effect of Vildagliptin and How the Body Changes the Blood Level of Vildagliptin in Healthy Chinese VolunteersCompletedNCT00419887Phase 1
• Bioequivalence of Vildagliptin Tablet Manufactured in China Compared to Imported Vildagliptin Tablet in Chinese Healthy VolunteersCompletedNCT00414947Phase 1
• Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin AloneCompletedNCT00396357Phase 3
• Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin AloneCompletedNCT00396227Phase 3
• Efficacy and Safety of Vildagliptin Compared to Placebo on the Incretin Effect in Patients With Type 2 Diabetes Treated With MetforminCompletedNCT00396071Phase 3
• Efficacy and Safety of Vildagliptin Versus Placebo in Patients With Type 2 DiabetesCompletedNCT00390520Phase 3
• Long Term Safety of Vildagliptin (100mg qd) In Patients With Type 2 DiabetesCompletedNCT00389415Phase 3
• Efficacy and Safety of Vildagliptin Compared to Metformin in Elderly Drug Naive Patients With Type 2 DiabetesCompletedNCT00383578Phase 3
• Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 DiabetesCompletedNCT00382096Phase 3
• Effect of Vildagliptin on Fat and Muscle Metabolism in Patients With Type 2 DiabetesCompletedNCT00380445Phase 3
• A Study to Assess the Acute Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes.CompletedNCT00380380Phase 3
• To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 DiabetesCompletedNCT00368134Phase 3
• A Study To Compare the Effect of Vildagliptin Compared to Placebo in Patients With Type 2 DiabetesCompletedNCT00351832Phase 3
• A Study to Evaluate the Effect of Vildagliptin on the Maximum Insulin Secretion in Patients With Type 2 DiabetesCompletedNCT00351585Phase 3
• A Study to Assess the Effects of DPP-4 Inhibition on Insulin Sensitivity in Type 2 DiabetesCompletedNCT00351546Phase 3
• A Study to Assess the Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 DiabetesCompletedNCT00351507Phase 3
• Long-Term Safety Study of Vildagliptin in Patients With Type 2 DiabetesCompletedNCT00325429Phase 3
• To Assess the Efficacy and Safety of Vildagliptin as Add-on Therapy to Sulfonylurea in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea MonotherapyCompletedNCT00325117Phase 3
• A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetesCompletedNCT00312130Phase 3
• A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild HyperglycemiaCompletedNCT00300287Phase 3
• A Clinical Study to Assess the Effect of Vildagliptin on Beta Cell Function in Drug Naive Patients With Type 2 DiabetesCompletedNCT00260156Phase 3
• A Clinical Study to Assess the Efficacy and Safety of Vildagliptin in Patients With Type 2 DiabetesCompletedNCT00238498Phase 2
• Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose ToleranceCompletedNCT00237250Phase 3
• Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 DiabetesCompletedNCT00237237Phase 3
• Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 DiabetesCompletedNCT00138619Phase 3
• Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 DiabetesCompletedNCT00138606Phase 3
• Extension to a Study of the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With Hemoglobin A1c (HbA1c) 9-11%CompletedNCT00138593Phase 3
• Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 DiabetesCompletedNCT00138580Phase 3
• Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 DiabetesCompletedNCT00138567Phase 3
• Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 DiabetesCompletedNCT00138554Phase 3
• Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 DiabetesCompletedNCT00138541Phase 3
• Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 DiabetesCompletedNCT00138515Phase 3
• Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 DiabetesCompletedNCT00120536Phase 3
• Efficacy and Safety of Vildagliptin Compared to Acarbose in Drug Naive Patients With Type 2 DiabetesCompletedNCT00110240Phase 3
• Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 DiabetesCompletedNCT00106340Phase 3
• Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 DiabetesCompletedNCT00102466Phase 3
• Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 DiabetesCompletedNCT00102388Phase 3
• Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 DiabetesCompletedNCT00101803Phase 3
• Efficacy and Safety of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes and Mild HyperglycemiaCompletedNCT00101712Phase 3
• Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11%CompletedNCT00101673Phase 3
• A Clinical Study to Assess the Effect of Vildagliptin on Postprandial Lipid Parameters in Patients With Type 2 DiabetesCompletedNCT00099957Phase 2
• Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 DiabetesCompletedNCT00099944Phase 3
• Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 DiabetesCompletedNCT00099931Phase 3
• Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 DiabetesCompletedNCT00099918Phase 3
• A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 DiabetesCompletedNCT00099905Phase 3
• Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 DiabetesCompletedNCT00099892Phase 3
• Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 DiabetesCompletedNCT00099866Phase 3
• Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 DiabetesCompletedNCT00099853Phase 3

← Vildagliptin overview